Fludarabine + Rituximab
From OncoWiki
Jump to navigationJump to search
Chronic Lymphocytic Leukemia
- Fludarabine 25 mg/m2/d iv d1-5
- Rituximab (Rituxan) 375 mg/m2 iv d1 and 4 of cycle 1, then d1 only for cycles 2-6
Q4w x 6 cycles
2 months later:
- Rituximab 375 mg/m2 iv qw x 4 doses
References
- Byrd JC et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B9712. Blood 2003; 101:6
- Byrd, JC et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105:49